睿知中国医院研究地图
候选清单

正在招募胰腺癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由宁波市医疗中心李惠利医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方宁波市医疗中心李惠利医院Ningbo Medical Center Lihuili Hospital宁波医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07892573,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 85 岁;性别:不限

    登记记录的入选字段

  2. EGFR positivity (1+/2+/3+) confirmed by immunohistochemistry.

    入选标准第 5 条

  3. For women of childbearing potential, a negative urine or serum pregnancy test within 3 days before the first administration of study drug (Day 1 of Cycle 1). Women who are not of childbearing potential are defined as postmenopausal for at least 1 year, or surgically sterilized, or having undergone hysterectomy. If there is any risk of conception, all participants must use a contraceptive measure with an annual failure rate of less than 1% throughout the treatment period and for 120 days after the last dose of study drug.

    入选标准第 10 条

    Previous treatment with an antibody-drug conjugate containing MMAE as the cytotoxic payload; previous use of S-1.

    排除标准第 2 条

    Incomplete recovery from the toxicity and/or complications of any prior intervention before the start of treatment, i.e. toxicity worse than grade 1 or above baseline, excluding alopecia or fatigue.

    排除标准第 16 条

  4. ECOG performance status of 0 to 3.

    入选标准第 6 条

  5. Current or recent (within 10 days before the first dose of study drug) continuous use for 10 days of aspirin (more than 325 mg/day) or of another non-steroidal anti-inflammatory drug known to inhibit platelet function.

    排除标准第 10 条

  6. The patient must have at least one measurable target lesion according to RECIST v1.1.

    入选标准第 7 条

  7. Diagnosis of another malignant disease within 5 years before the first dose (excluding radically treated basal cell carcinoma and squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ).

    排除标准第 1 条

    Known history of human immunodeficiency virus infection, i.e. positive for HIV 1/2 antibody.

    排除标准第 17 条

    Untreated active hepatitis B, defined as HBsAg positive with detectable HBV-DNA copy number above the upper limit of normal of the local laboratory.

    排除标准第 18 条

  8. Pregnant or lactating women.

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07892573,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Understands the study procedures and content and voluntarily signs written informed consent.
  2. Age: 18 years or older.
  3. Histopathologically confirmed pancreatic cancer.
  4. The participant must have evidence of recurrence or metastasis, or have been assessed as not amenable to complete surgical resection, and must have received at least one prior line of standard systemic pharmacotherapy.
  5. EGFR positivity (1+/2+/3+) confirmed by immunohistochemistry.
  6. ECOG performance status of 0 to 3.
  7. The patient must have at least one measurable target lesion according to RECIST v1.1.
  8. Adequate organ and bone marrow function; screening laboratory tests must meet all of the following criteria: hemoglobin greater than 9 g/dL without transfusion or erythropoietin within the preceding 14 days; absolute neutrophil count of 1.5 x 10\^9/L or higher without the use of granulocyte colony-stimulating factor within the preceding 14 days; platelets of 80 x 10\^9/L or higher without transfusion within the preceding 14 days; total bilirubin of 1.5 x upper limit of normal or less (up to 3 x upper limit of normal permitted for Gilbert syndrome), ALT and AST of 2.5 x upper limit of normal or less (5 x upper limit of normal permitted in the presence of liver metastases); serum creatinine of 1.5 x upper limit of normal or less, or creatinine clearance of 50 mL/min or higher according to the Cockcroft-Gault formula; adequate coagulation function, defined as an international normalized ratio or prothrombin time of 1.5 x upper limit of normal or less; and normal thyroid function, defined as thyroid-stimulating hormone within the normal range, although participants with an out-of-range baseline thyroid-stimulating hormone may be enrolled if total T3 (or FT3) and FT4 are within the normal range.
  9. Expected survival of more than 3 months.
  10. For women of childbearing potential, a negative urine or serum pregnancy test within 3 days before the first administration of study drug (Day 1 of Cycle 1). Women who are not of childbearing potential are defined as postmenopausal for at least 1 year, or surgically sterilized, or having undergone hysterectomy. If there is any risk of conception, all participants must use a contraceptive measure with an annual failure rate of less than 1% throughout the treatment period and for 120 days after the last dose of study drug.
  11. The participant is able and willing to comply with the visits, treatment plan, laboratory tests and other study-related procedures specified in the protocol.

排除标准:Exclusion Criteria:

  1. Diagnosis of another malignant disease within 5 years before the first dose (excluding radically treated basal cell carcinoma and squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ).
  2. Previous treatment with an antibody-drug conjugate containing MMAE as the cytotoxic payload; previous use of S-1.
  3. Current participation in an interventional clinical study, or receipt of another investigational drug or treatment with an investigational device within 4 weeks before the first dose.
  4. Systemic treatment within 2 weeks before the first dose with a Chinese patent medicine having an antitumor indication, or with an immunomodulatory agent (including thymosin, interferon and interleukin), except for local administration for the control of pleural effusion.
  5. Active autoimmune disease requiring systemic treatment (for example disease-modifying agents, glucocorticoids or immunosuppressants) within 2 years before the first dose. Replacement therapy (for example thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency) is not considered systemic treatment.
  6. Radiological evidence of tumor invasion or infiltration of a major blood vessel, or a bleeding tendency assessed by the investigator or the radiologist.
  7. Major surgery (excluding surgery performed for the purpose of biopsy) within 4 weeks before the first dose of study drug, or planned major surgery during the study period.
  8. Serious non-healing wound, ulcer or fracture.
  9. Minor surgery (outpatient or inpatient procedure requiring local anesthesia, including placement of a central venous catheter) within 48 hours before the first dose of study drug.
  10. Current or recent (within 10 days before the first dose of study drug) continuous use for 10 days of aspirin (more than 325 mg/day) or of another non-steroidal anti-inflammatory drug known to inhibit platelet function.
  11. Current or recent (within 10 days before the first dose of study drug) treatment for 10 consecutive days with a full-dose oral or parenteral anticoagulant or thrombolytic agent. Note: prophylactic low-dose anticoagulation is permitted provided the international normalized ratio is 1.5 or less, in which case low-dose warfarin (1 mg/day or less), low-dose heparin (12,000 U/day or less) or low-dose aspirin (100 mg/day or less) may be used for prophylactic purposes.
  12. Hereditary bleeding tendency or coagulation disorder, or a history of thrombosis.
  13. Clinically uncontrollable pleural or peritoneal effusion (participants who do not require drainage, or in whom the effusion does not increase significantly after 3 days without drainage, may be enrolled).
  14. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
  15. Known hypersensitivity to becotatug vedotin, anti-PD-1, or any active ingredient or excipient of these study drugs.
  16. Incomplete recovery from the toxicity and/or complications of any prior intervention before the start of treatment, i.e. toxicity worse than grade 1 or above baseline, excluding alopecia or fatigue.
  17. Known history of human immunodeficiency virus infection, i.e. positive for HIV 1/2 antibody.
  18. Untreated active hepatitis B, defined as HBsAg positive with detectable HBV-DNA copy number above the upper limit of normal of the local laboratory.
  19. Administration of a live vaccine within 30 days before the first dose (Day 1 of Cycle 1). Note: administration of an injectable inactivated seasonal influenza vaccine within 30 days before the first dose is permitted; intranasal live attenuated influenza vaccine is not permitted.
  20. Any medical history, disease evidence, treatment or abnormal laboratory value likely to interfere with the study results or to prevent full participation in the study, or any other condition judged by the investigator to carry an unacceptable risk, including severe or uncontrolled systemic disease such as unstable angina, congestive heart failure, chronic heart failure of New York Heart Association class 2 or higher; any arterial thrombosis, embolism or ischemia within 6 months before enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack; poorly controlled blood pressure (systolic blood pressure above 140 mmHg or diastolic blood pressure above 90 mmHg); active tuberculosis; active or uncontrolled infection requiring systemic treatment; clinically active diverticulitis, abdominal abscess or gastrointestinal obstruction; or a psychiatric disorder precluding cooperation with treatment.
  21. Pregnant or lactating women.

引自 ClinicalTrials.gov, NCT07892573, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07892573,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07892573